Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 102 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Eleftheriadis, Theodoros  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
Eleftheriadis, T., Pissas G., Liakopoulos V., & Stefanidis I. (2018).  IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T‑cell survival and proliferation.. Int J Mol Med. 42(1), 557-568.
Eleftheriadis, T., Sounidaki M., Pissas G., Antoniadi G., Liakopoulos V., & Stefanidis I. (2016).  In human alloreactive CD4⁺ T-cells, dichloroacetate inhibits aerobic glycolysis, induces apoptosis and favors differentiation towards the regulatory T-cell subset instead of effector T-cell subsets.. Mol Med Rep. 13(4), 3370-6.
Eleftheriadis, T., Pissas G., Mavropoulos A., Nikolaou E., Filippidis G., Liakopoulos V., et al. (2020).  In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.. Arch Immunol Ther Exp (Warsz). 68(6), 31.
Eleftheriadis, T., Pissas G., Antoniadi G., Tsogka K., Makri P., Liakopoulos V., et al. (2016).  Increased Indoleamine 2,3-Dioxygenase in Monocytes of Patients on Hemodialysis.. Iran J Kidney Dis. 10(2), 91-3.
Eleftheriadis, T., Kartsios C., Pissas G., Liakopoulos V., Antoniadi G., Galaktidou G., et al. (2013).  Increased plasma angiogenin level is associated and may contribute to decreased T-cell zeta-chain expression in hemodialysis patients.. Ther Apher Dial. 17(1), 48-54.
Eleftheriadis, T., Pissas G., Remoundou M., Antoniadi G., Liakopoulos V., & Stefanidis I. (2013).  Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin.. Ren Fail. 35(10), 1399-403.
Eleftheriadis, T., Pissas G., Liakopoulos V., & Stefanidis I. (2018).  Indoleamine 2, 3-dioxygenase Up-regulates Hypoxia-inducible Factor-1α Expression by Degrading L-tryptophan but Not Its Activity in Human Alloreactive T-cells.. Iran J Allergy Asthma Immunol. 17(1), 56-67.
Eleftheriadis, T., Pissas G., Sounidaki M., Tsogka K., Antoniadis N., Antoniadi G., et al. (2016).  Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.. Int J Mol Med. 38(5), 1605-1613.
Eleftheriadis, T., Pissas G., Golfinopoulos S., Liakopoulos V., & Stefanidis I. (2022).  Indoleamine 2,3-dioxygenase controls purinergic receptor-mediated ischemia-reperfusion injury in renal tubular epithelial cells.. J Basic Clin Physiol Pharmacol.
Eleftheriadis, T., Pissas G., Antoniadi G., Liakopoulos V., & Stefanidis I. (2015).  Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.. Immunology. 146(2), 292-300.
Eleftheriadis, T., Pissas G., Antoniadi G., Spanoulis A., Liakopoulos V., & Stefanidis I. (2014).  Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.. Int Immunol. 26(12), 673-84.
Eleftheriadis, T., Liakopoulos V., Antoniadi G., Stefanidis I., & Galaktidou G. (2011).  Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination.. Vaccine. 29(12), 2242-7.
Sounidaki, M., Pissas G., Eleftheriadis T., Antoniadi G., Golfinopoulos S., Liakopoulos V., et al. (2019).  Indoleamine 2,3-dioxygenase suppresses humoral alloimmunity via pathways that different to those associated with its effects on T cells.. Biomed Rep. 1(1), 1-5.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.